Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study

Abstract Background The recurrence rate of cholangiocarcinoma (CCA) is high, and there are currently no evidence-based treatments for recurrent CCA. This study aimed to evaluate the effectiveness and safety of programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibito...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Lihui Lin, Yansong Lin, Wei Chen, Xia Yang, Xianwen Guo, Yanqin Wu, Xiaoyu Yin, Zhen Ding, Jingping Yun
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2025-07-01
Serija:	BMC Cancer
Teme:	Cholangiocarcinoma Recurrent PD-1 PD-L1 Efficacy Safety
Online dostop:	https://doi.org/10.1186/s12885-025-14459-4
Oznake:	Označite Brez oznak, prvi označite!